BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma

Abstract

Our study identifies and validates BRD9 as a novel therapeutic target in preclinical models of multiple myeloma, which provides the framework for the clinical evaluation of BRD9 degraders to improve patient outcome.